Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

4.2%

23 terminated/withdrawn out of 551 trials

Success Rate

92.3%

+5.8% vs industry average

Late-Stage Pipeline

23%

125 trials in Phase 3/4

Results Transparency

9%

26 of 276 completed trials have results

Key Signals

65 recruiting26 with results21 terminated

Enrollment Performance

Analytics

N/A
198(50.5%)
Phase 4
86(21.9%)
Phase 2
53(13.5%)
Phase 3
39(9.9%)
Phase 1
16(4.1%)
392Total
N/A(198)
Phase 4(86)
Phase 2(53)
Phase 3(39)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (551)

Showing 20 of 551 trials
NCT06099366Phase 2Recruiting

Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in Children

Role: collaborator

NCT07719894Phase 4Recruiting

Cilostazol and Aspirin for Cardiovascular Event Prevention in Patients With Type 2 Diabetes

Role: lead

NCT07714278Not ApplicableEnrolling By Invitation

Effectiveness of Video-Based Movement Analysis-Guided Personalized Rehabilitation in Patients With CIPN: A Multicenter Trial

Role: lead

NCT05148286Phase 4Recruiting

Albumin and Crystalloid Administration in Septic Shock

Role: collaborator

NCT07683949Phase 1Enrolling By Invitation

Clinical Trial Evaluating the Efficacy of Capecitabine Plus Lenvatinib in Patients With Advanced Colorectal Cancer Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidine

Role: lead

NCT07674719Not ApplicableNot Yet Recruiting

Remimazolam on the Incidence of Postoperative Acute Kidney Injury

Role: lead

NCT07631156Phase 4Not Yet Recruiting

STEPwise De-escalation and Optimizing Withdrawal of ARNI and SGLT2i in Normalized Heart Failure

Role: collaborator

NCT05525858Recruiting

KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II

Role: lead

NCT07572032Phase 4Recruiting

Delayed Initiation of ARNI and SGLT2i in Heart Failure With Corrected Aetiology (DELAY-HF), Pilot Study

Role: collaborator

NCT07613268Not ApplicableNot Yet Recruiting

Exploratory Trial of the "HiDongDong" Language Rehabilitation App for Articulation Delay.

Role: lead

NCT06388720Phase 2Recruiting

The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy

Role: collaborator

NCT07062536Phase 2Not Yet Recruiting

mFOLFOX/mFOLFIRI vs. mFOLFOX in Advanced or Recurrent Biliary Tract Cancer Second-line

Role: lead

NCT05557123Not ApplicableCompleted

Mobile App for Improving Adherence of Rivoxaban (RIVOX-AF)

Role: lead

NCT05553314Phase 4Completed

Carvedilol in HF With Preserved EF

Role: lead

NCT07590843Completed

Efficacy and Safety of a Novel Monopolar Radiofrequency Device for Mid and Lower Face Rejuvenation

Role: lead

NCT07497867Recruiting

Long-term Prospective Study of Korean CADASIL Patients

Role: collaborator

NCT05365438Phase 4Recruiting

Atmeg (Atorvastatin and Omega-3 Combination) and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia

Role: lead

NCT06402747Phase 4Recruiting

Clopidogrel Versus Cilostazol on Vessels

Role: lead

NCT05365425Phase 4Recruiting

Choline Fenofibrate and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia

Role: lead

NCT03331718Phase 3Completed

PoLyglycolic Acid Felt reiNforcEmenT of the PancreaticoJejunostomy (PLANET-PJ Trial)

Role: collaborator